Business Description
Encompass Health Corp
NAICS : 621498
SIC : 8082
ISIN : US29261A1007
Total Employee Number:
29,944Compare
Compare
Traded in other countries / regions
EHC.USAEHC.MexicoHSOA.Germany IPO Date
2013-05-20Description
Encompass Health Corp is a US-based provider of post-acute healthcare services, operating the largest network of inpatient rehabilitation hospitals in the United States. Its inpatient rehabilitation segment generates nearly all revenue and treats patients recovering from strokes and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. Facilities offer intensive, physician-led rehabilitation with multidisciplinary teams of nurses and therapists. Encompass Health also provides home health and hospice services through its Enhabit segment, though it has announced plans to separate that business. The company operates hospitals across numerous states, with concentrations in the South, Texas, and other populous markets, and derives revenue primarily from Medicare, Medicare Advantage, and commercial insurers, with some Medicaid and managed care. It also holds joint ventures with health systems and hospitals.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.04 | |||||
Equity-to-Asset | 0.35 | |||||
Debt-to-Equity | 1.09 | |||||
Debt-to-EBITDA | 1.9 | |||||
Interest Coverage | 8.89 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 3.47 | |||||
Beneish M-Score | -2.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.3 | |||||
3-Year EBITDA Growth Rate | 16.6 | |||||
3-Year EPS without NRI Growth Rate | 24.1 | |||||
3-Year FCF Growth Rate | 52.5 | |||||
3-Year Book Growth Rate | 22.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.25 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.43 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.55 | |||||
9-Day RSI | 56.54 | |||||
14-Day RSI | 56.94 | |||||
3-1 Month Momentum % | 23.53 | |||||
6-1 Month Momentum % | 19.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.19 | |||||
Quick Ratio | 1.19 | |||||
Cash Ratio | 0.12 | |||||
Days Sales Outstanding | 37.71 | |||||
Days Payable | 257.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.61 | |||||
Dividend Payout Ratio | 0.13 | |||||
3-Year Dividend Growth Rate | -5.8 | |||||
Forward Dividend Yield % | 0.69 | |||||
5-Year Yield-on-Cost % | 0.33 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 2.46 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 95.82 | |||||
Operating Margin % | 18 | |||||
Net Margin % | 10.01 | |||||
EBITDA Margin % | 24.17 | |||||
FCF Margin % | 6.57 | |||||
OCF Margin % | 19.34 | |||||
ROE % | 25.43 | |||||
ROA % | 8.74 | |||||
ROIC % | 14.04 | |||||
3-Year ROIIC % | 27.47 | |||||
ROC (Joel Greenblatt) % | 26.22 | |||||
ROCE % | 18.43 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.39 | |||||
Forward PE Ratio | 18.57 | |||||
PE Ratio without NRI | 21.35 | |||||
Shiller PE Ratio | 27.9 | |||||
Price-to-Owner-Earnings | 32.02 | |||||
PEG Ratio | 1.74 | |||||
PS Ratio | 2.04 | |||||
PB Ratio | 4.77 | |||||
Price-to-Tangible-Book | 12.66 | |||||
Price-to-Free-Cash-Flow | 30.65 | |||||
Price-to-Operating-Cash-Flow | 10.45 | |||||
EV-to-EBIT | 13.68 | |||||
EV-to-Forward-EBIT | 13.4 | |||||
EV-to-EBITDA | 10.52 | |||||
EV-to-Forward-EBITDA | 9.91 | |||||
EV-to-Revenue | 2.54 | |||||
EV-to-Forward-Revenue | 2.13 | |||||
EV-to-FCF | 37.75 | |||||
Price-to-GF-Value | 1.05 | |||||
Price-to-Projected-FCF | 1.86 | |||||
Price-to-DCF (Earnings Based) | 1.69 | |||||
Price-to-DCF (FCF Based) | 2.62 | |||||
Price-to-Median-PS-Value | 1.48 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.83 | |||||
Price-to-Graham-Number | 3.45 | |||||
Earnings Yield (Greenblatt) % | 7.31 | |||||
FCF Yield % | 3.39 | |||||
Forward Rate of Return (Yacktman) % | 13.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Encompass Health Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5,321.37 | ||
| EPS (TTM) (€) | 5.265 | ||
| Beta | 0.2082 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 1.1 | ||
| Volatility % | 27.76 | ||
| 14-Day RSI | 56.94 | ||
| 14-Day ATR (€) | 1.149282 | ||
| 20-Day SMA (€) | 104.2 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 78 - 109 | ||
| Shares Outstanding (Mil) | 98.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Encompass Health Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Encompass Health Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 157 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-05 10:00 | In 137 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-05 | In 136 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 10:00 | In 39 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 37 days | ||
| USD 0.210000 Cash Dividend | 2026-10-01 | In 9 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 10:00 | 95.00 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 97.00 (+0.00%) | ||
| USD 0.190000 Cash Dividend | 2026-07-01 | 88.00 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 08:40 | 89.50 (+0.00%) |
Show
Entries
Encompass Health Corp Frequently Asked Questions
What is Encompass Health Corp(FRA:HSOA)'s stock price today?
The current price of FRA:HSOA is €106.00. The 52 week high of FRA:HSOA is €109.00 and 52 week low is €78.00.
When is next earnings date of Encompass Health Corp(FRA:HSOA)?
The next earnings date of Encompass Health Corp(FRA:HSOA) is 2026-10-29 Est..
Does Encompass Health Corp(FRA:HSOA) pay dividends? If so, how much?
The Dividend Yield %  of Encompass Health Corp(FRA:HSOA) is 0.61% (As of Today), Highest Dividend Payout Ratio of Encompass Health Corp(FRA:HSOA) was 0.39. The lowest was 0.13. And the median was 0.29. The  Forward Dividend Yield % of Encompass Health Corp(FRA:HSOA) is 0.69%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers